Régions déterminant la complémentarité : Questions médicales fréquentes
Nom anglais: Complementarity Determining Regions
Descriptor UI:D022801
Tree Number:G02.111.570.060.425.160
Termes MeSH sélectionnés :
Gain of Function Mutation
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Régions déterminant la complémentarité : Questions médicales les plus fréquentes",
"headline": "Régions déterminant la complémentarité : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Régions déterminant la complémentarité : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-06",
"dateModified": "2025-03-03",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Régions déterminant la complémentarité"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Région variable d'immunoglobuline",
"url": "https://questionsmedicales.fr/mesh/D007135",
"about": {
"@type": "MedicalCondition",
"name": "Région variable d'immunoglobuline",
"code": {
"@type": "MedicalCode",
"code": "D007135",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G02.111.570.060.425"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Régions déterminant la complémentarité",
"alternateName": "Complementarity Determining Regions",
"code": {
"@type": "MedicalCode",
"code": "D022801",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Boris I Chobrutskiy",
"url": "https://questionsmedicales.fr/author/Boris%20I%20Chobrutskiy",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine, Oregon Health and Science University Hospital, Portland, Oregon, USA."
}
},
{
"@type": "Person",
"name": "George Blanck",
"url": "https://questionsmedicales.fr/author/George%20Blanck",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA."
}
},
{
"@type": "Person",
"name": "Elena S Klimtchuk",
"url": "https://questionsmedicales.fr/author/Elena%20S%20Klimtchuk",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Daniele Peterle",
"url": "https://questionsmedicales.fr/author/Daniele%20Peterle",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Lawreen H Connors",
"url": "https://questionsmedicales.fr/author/Lawreen%20H%20Connors",
"affiliation": {
"@type": "Organization",
"name": ""
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "A Pedigree Investigation of H-antigen Deletion Caused by Mutation of 658 C to T in the FUT1 Gene.",
"datePublished": "2023-05-24",
"url": "https://questionsmedicales.fr/article/39011245",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12288-023-01669-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "KRAS G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma.",
"datePublished": "2023-05-24",
"url": "https://questionsmedicales.fr/article/37253296",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.lungcan.2023.107254"
}
},
{
"@type": "ScholarlyArticle",
"name": "Quantitative Mutation Analysis of Genes and Proteins of Major SARS-CoV-2 Variants of Concern and Interest.",
"datePublished": "2023-05-18",
"url": "https://questionsmedicales.fr/article/37243278",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/v15051193"
}
},
{
"@type": "ScholarlyArticle",
"name": "Asymmetric presentation with a novel RP2 gene mutation in X-Linked retinitis pigmentosa: a case report.",
"datePublished": "2023-05-17",
"url": "https://questionsmedicales.fr/article/37198560",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12886-023-02968-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "RUNX2 mutation inhibits the cellular senescence of dental follicle cells via ERK signalling pathway.",
"datePublished": "2023-05-08",
"url": "https://questionsmedicales.fr/article/37154397",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/odi.14607"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes chimiques",
"item": "https://questionsmedicales.fr/mesh/D055598"
},
{
"@type": "ListItem",
"position": 3,
"name": "Phénomènes biochimiques",
"item": "https://questionsmedicales.fr/mesh/D001669"
},
{
"@type": "ListItem",
"position": 4,
"name": "Région variable d'immunoglobuline",
"item": "https://questionsmedicales.fr/mesh/D007135"
},
{
"@type": "ListItem",
"position": 5,
"name": "Régions déterminant la complémentarité",
"item": "https://questionsmedicales.fr/mesh/D022801"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Régions déterminant la complémentarité - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Régions déterminant la complémentarité",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Régions déterminant la complémentarité",
"description": "Comment identifier les CDR dans un anticorps ?\nQuels tests révèlent la présence de CDR ?\nLes CDR peuvent-ils être visualisés ?\nQuel rôle joue la bioinformatique dans l'étude des CDR ?\nLes CDR sont-ils spécifiques à chaque anticorps ?",
"url": "https://questionsmedicales.fr/mesh/D022801?mesh_terms=Gain+of+Function+Mutation&page=997#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Régions déterminant la complémentarité",
"description": "Quels symptômes indiquent une réponse immunitaire anormale ?\nLes CDR affectent-ils les symptômes d'infections ?\nComment les CDR influencent-ils les maladies allergiques ?\nLes CDR sont-ils liés à des symptômes de maladies auto-immunes ?\nPeut-on prédire des symptômes grâce aux CDR ?",
"url": "https://questionsmedicales.fr/mesh/D022801?mesh_terms=Gain+of+Function+Mutation&page=997#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Régions déterminant la complémentarité",
"description": "Comment prévenir les maladies liées aux CDR ?\nLes CDR peuvent-ils être ciblés pour la prévention ?\nQuel rôle joue l'alimentation dans la prévention des maladies liées aux CDR ?\nLes tests génétiques aident-ils à prévenir les maladies liées aux CDR ?\nComment le mode de vie influence-t-il la prévention des maladies ?",
"url": "https://questionsmedicales.fr/mesh/D022801?mesh_terms=Gain+of+Function+Mutation&page=997#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Régions déterminant la complémentarité",
"description": "Comment les CDR sont-ils utilisés en thérapie ?\nLes traitements ciblant les CDR sont-ils efficaces ?\nQuels types de médicaments ciblent les CDR ?\nLes CDR peuvent-ils être modifiés pour améliorer les traitements ?\nQuels sont les effets secondaires des traitements ciblant les CDR ?",
"url": "https://questionsmedicales.fr/mesh/D022801?mesh_terms=Gain+of+Function+Mutation&page=997#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Régions déterminant la complémentarité",
"description": "Quelles complications peuvent survenir avec des CDR défectueux ?\nLes CDR sont-ils impliqués dans des complications infectieuses ?\nComment les CDR affectent-ils les traitements anticancéreux ?\nLes complications liées aux CDR peuvent-elles être traitées ?\nQuels sont les risques de complications lors de thérapies ciblant les CDR ?",
"url": "https://questionsmedicales.fr/mesh/D022801?mesh_terms=Gain+of+Function+Mutation&page=997#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Régions déterminant la complémentarité",
"description": "Quels facteurs augmentent le risque de maladies liées aux CDR ?\nL'âge influence-t-il le risque lié aux CDR ?\nLe stress a-t-il un impact sur les CDR ?\nLes infections antérieures influencent-elles les CDR ?\nComment le mode de vie affecte-t-il les CDR ?",
"url": "https://questionsmedicales.fr/mesh/D022801?mesh_terms=Gain+of+Function+Mutation&page=997#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les CDR dans un anticorps ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les CDR sont identifiés par séquençage et analyse des structures d'anticorps."
}
},
{
"@type": "Question",
"name": "Quels tests révèlent la présence de CDR ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'affinité et de liaison aux antigènes sont utilisés pour détecter les CDR."
}
},
{
"@type": "Question",
"name": "Les CDR peuvent-ils être visualisés ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, par des techniques comme la cristallographie aux rayons X ou la RMN."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la bioinformatique dans l'étude des CDR ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "La bioinformatique aide à prédire et modéliser les CDR à partir de séquences d'anticorps."
}
},
{
"@type": "Question",
"name": "Les CDR sont-ils spécifiques à chaque anticorps ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, chaque anticorps a des CDR uniques qui déterminent sa spécificité."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une réponse immunitaire anormale ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des allergies ou des maladies auto-immunes peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les CDR affectent-ils les symptômes d'infections ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des CDR efficaces peuvent réduire la gravité des symptômes d'infections."
}
},
{
"@type": "Question",
"name": "Comment les CDR influencent-ils les maladies allergiques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des CDR spécifiques peuvent reconnaître des allergènes, entraînant des réactions."
}
},
{
"@type": "Question",
"name": "Les CDR sont-ils liés à des symptômes de maladies auto-immunes ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des CDR mal régulés peuvent cibler des tissus sains, provoquant des symptômes."
}
},
{
"@type": "Question",
"name": "Peut-on prédire des symptômes grâce aux CDR ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études sur les CDR peuvent aider à prédire la réponse immunitaire et les symptômes."
}
},
{
"@type": "Question",
"name": "Comment prévenir les maladies liées aux CDR ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vaccination et l'éducation sur les allergies peuvent aider à prévenir ces maladies."
}
},
{
"@type": "Question",
"name": "Les CDR peuvent-ils être ciblés pour la prévention ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des stratégies de vaccination ciblant les CDR peuvent prévenir certaines infections."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'alimentation dans la prévention des maladies liées aux CDR ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut renforcer le système immunitaire et prévenir les maladies."
}
},
{
"@type": "Question",
"name": "Les tests génétiques aident-ils à prévenir les maladies liées aux CDR ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les risques et guider la prévention."
}
},
{
"@type": "Question",
"name": "Comment le mode de vie influence-t-il la prévention des maladies ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant exercice et gestion du stress, aide à prévenir les maladies."
}
},
{
"@type": "Question",
"name": "Comment les CDR sont-ils utilisés en thérapie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les CDR sont ciblés pour développer des anticorps thérapeutiques contre des maladies."
}
},
{
"@type": "Question",
"name": "Les traitements ciblant les CDR sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils montrent une efficacité dans le traitement de diverses maladies, y compris le cancer."
}
},
{
"@type": "Question",
"name": "Quels types de médicaments ciblent les CDR ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anticorps monoclonaux et des inhibiteurs de points de contrôle immunitaire ciblent les CDR."
}
},
{
"@type": "Question",
"name": "Les CDR peuvent-ils être modifiés pour améliorer les traitements ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la modification des CDR peut augmenter l'affinité et la spécificité des anticorps."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des traitements ciblant les CDR ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des réactions immunitaires indésirables et des allergies."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des CDR défectueux ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des CDR défectueux peuvent entraîner des maladies auto-immunes et des allergies."
}
},
{
"@type": "Question",
"name": "Les CDR sont-ils impliqués dans des complications infectieuses ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des CDR inefficaces peuvent aggraver les infections et retarder la guérison."
}
},
{
"@type": "Question",
"name": "Comment les CDR affectent-ils les traitements anticancéreux ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des CDR mal ciblés peuvent réduire l'efficacité des traitements anticancéreux."
}
},
{
"@type": "Question",
"name": "Les complications liées aux CDR peuvent-elles être traitées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements ciblés peuvent gérer les complications associées aux CDR."
}
},
{
"@type": "Question",
"name": "Quels sont les risques de complications lors de thérapies ciblant les CDR ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des réactions immunitaires indésirables et des effets secondaires graves."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de maladies liées aux CDR ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme la génétique, l'environnement et le mode de vie augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque lié aux CDR ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vieillissement peut affecter la fonction des CDR et augmenter le risque de maladies."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur les CDR ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut altérer la réponse immunitaire et affecter les CDR."
}
},
{
"@type": "Question",
"name": "Les infections antérieures influencent-elles les CDR ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des infections passées peuvent modifier la structure et la fonction des CDR."
}
},
{
"@type": "Question",
"name": "Comment le mode de vie affecte-t-il les CDR ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut améliorer la fonction des CDR et réduire le risque de maladies."
}
}
]
}
]
}
H-antigen deletion is often caused by FUT1 gene mutation, which is a very rare blood group. In this case, the H-antigen phenotype, FUT1, FUT2 sequences, and family genetic investigation of a 26-year-o...
KRAS G12C mutations are found in about 12-13% of LUAD samples and it is unclear whether they are associated with worse survival outcomes in resected, stage I LUAD. We assessed whether KRAS-G12C mutate...
Of various SARS-CoV-2 variants, some have drawn special concern or interest because of their heightened disease threat. The mutability of individual SARS-CoV-2 genes/proteins presumably varies. The pr...
We present the detailed multimodal imaging analysis in a case of X-linked retinitis pigmentosa (XLRP) exhibiting a markedly asymmetric presentation with a novel RP2 mutation....
A 25-year-old woman complained of decreased vision in the right eye as well as night blindness. Her visual acuity was 20/100 (OD) and 20/20 (OS). Fundus examination revealed bone spicule pigmentation ...
Random X-inactivation may be attributed to interocular differences in the severity of XLRP in female carriers. A novel frameshift mutation in the RP2 gene and a comprehensive phenotypic evaluation in ...
The aim of this study was to explore the regulatory effect of RUNX2 mutation on dental follicle cells (DFCs) senescence and clarify the underlying mechanism. This study aimed to explore the basis for ...
Dental follicles were collected from a CCD patient and healthy controls. Senescence-associated β-galactosidase (SA-β-gal) staining, Ki67 staining, cell cycle assays, and senescence-related gene and pr...
RUNX2 mutation inhibited the cellular senescence of DFCs from the CCD patient compared with healthy controls. Ki67 staining showed that mutant RUNX2 promoted DFCs proliferation, and cell cycle assays ...
RUNX2 mutation delayed DFCs senescence through the ERK signalling pathway, which may be responsible for delayed permanent tooth eruption in CCD patients....
Adenosine deaminase (ADA) is a key enzyme in the purine salvage pathway. Genetic defects of the ADA gene can cause a subtype of severe combined immunodeficiency. To date, few Chinese cases have been r...
We retrospectively reviewed the medical records of patients diagnosed with ADA deficiency in Beijing Children's Hospital and summarized the previously published ADA deficiency cases from China in the ...
Nine patients were identified with two novel mutations (W272X and Q202 =). Early-onset infection, thymic abnormalities and failure to thrive were the most common manifestations of Chinese ADA-deficien...
This study described the first case series of Chinese ADA-deficient patients. Early-onset infection, thymic abnormalities and failure to thrive were the most common manifestations in our patients. We ...
Xeroderma pigmentosum (XP) is a genetic disorder caused by mutations in genes of the Nucleotide Excision Repair (NER) pathway (groups A-G) or in Translesion Synthesis DNA polymerase η (V). XP is assoc...
Adaptation to selective pressures is crucial for clinically important pathogens to establish epidemics, but the underlying evolutionary drivers remain poorly understood. The current epidemic of carbap...
Eosinophilic solid and cystic renal cell carcinoma (ESC-RCC) is an under-recognized, emerging new entity of sporadic renal neoplasms, which is listed as a rare type of renal cell carcinoma in the 2022...
We report one case of ESC-RCC, a 53-year-old female patient with a right kidney mass found during clinical examination. The patient experienced no discomforting symptoms. Computer-tomography imaging a...
The distinct morphological, immunophenotypic, and molecular characteristics of ESC-RCC we describe here, based on our case and the relevant literature, highlight the key points of the pathological and...
In recent years, tumour immunotherapy has ushered in a new era of oncology treatment. However, the use of immune checkpoint inhibitors (ICIs) in the treatment of CRC remains limited. There is an urgen...
We collected mutational and clinical data from cohorts of CRC patients treated with ICIs. The relationship between NOTCH pathway mutations (NOTCH-MT) and CRC immunotherapy prognosis was analysed using...
We observed greater infiltration of M1 macrophages, CD8+ T cells, neutrophils, and activated natural killer (NK) cells with NOTCH-MT status. Immunogenicity was also significantly higher in patients wi...
NOTCH-MT status was strongly associated with the prognosis of CRC patients treated with ICIs and is expected to serve as a novel biomarker and therapeutic target for CRC....